- Home
- CMMB vs TLPH Comparison
CMMB vs TLPH Comparison
Compare CMMB & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | TLPH |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 64.7M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | CMMB | TLPH |
|---|---|---|
| Price | $1.85 | $1.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $26.50 | $6.00 |
| AVG Volume (30 Days) | 95.6K | ★ 430.0K |
| Earning Date | 11-20-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $28,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14,267.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.73 | $0.38 |
| 52 Week High | $9.84 | $1.57 |
Technical Indicators
Market Signals| Indicator | CMMB | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 28.56 | 39.09 |
| Support Level | $2.01 | $1.20 |
| Resistance Level | $2.21 | $1.25 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 17.31 | 20.31 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.